Saturday, November 09, 2024 5:47:34 PM
Transforming Diabetes Management
Zachary Smith commented, "ADHC provides the ideal platform for the commercialization of GlucoGuard. Both Bill and I are eager to bring this life-saving technology to market, helping millions of diabetic patients-both adults and children-better manage their glucose levels with greater safety and ease."
Bill Colone added, "Hypoglycemia, particularly during sleep, is a persistent and dangerous issue for diabetic patients, often leading to serious consequences like the dreaded 'Death in Bed' syndrome. GlucoGuard's technology offers a game-changing solution to this pressing problem."
Key Development Partnerships
The GlucoGuard system is being developed in collaboration with three key partners:
A leading U.S. research university.
A highly respected biomedical and defense engineering firm.
A top publicly traded company in the Continuous Glucose Monitoring (CGM) sector.
Further details on these collaborations will be disclosed soon.
Cutting-Edge Technology for Unmet Medical Needs
GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest.
"The GlucoGuard invention is a significant leap forward in addressing one of the most dangerous complications of diabetes," said ADHC management. "We are thrilled to welcome Zachary Smith and his innovative team to ADHC, and we're committed to fast-tracking the development and commercialization of this much-needed technology."
About Artificial Intelligence and Health Care
A recent report from the Mayo Clinic identified three potential benefits of AI in healthcare:
Improving outcomes for both patients and clinical teams.
Lowering healthcare costs.
Benefitting population health.
From preventive screenings to diagnosis and treatment, AI is being used throughout the continuum of care today. Two examples are Preventive Health Care and Risk Assessment.
Cancer Screenings that use radiology can leverage AI to help produce results faster. A noted example is analyzing kidney images in a laborious 45 minute process. AI automated process can reduce this analysis to minutes, saving time, money and giving a more accurate diagnosis.
Pre-diabetes patients with no notable symptoms can be screened using AI to determine which type of diabetes they are at risk for and begin preventative care.
See AI in healthcare: The future of patient care and health management - Mayo Clinic Press.
About the Diabetes Market
The diabetes market is poised for substantial growth, with the U.S. market valued at $28 billion, underscoring the vast potential for GlucoGuard's adoption.
For more information on the $28 billion diabetes market, visit: United States Diabetes Market Report.
The Continuous Glucose Monitoring (CGM) sector, valued at $6.8 billion, further emphasizes the critical demand for advanced glucose management solutions.
For details on the CGM market, visit: Continuous Glucose Monitoring Market.
Cannot view this image? Visit: https://images.newsfilecorp.com/files/7822/224435_0235dd85640e0901_001full.jpg
Image 1
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/224435_0235dd85640e0901_001full.jpg
About IMD Solutions, Inc.
IMD Solutions, Inc. is a Nevada-based medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, IMD Solutions is at the forefront of diabetes management technology.
For more information, visit: www.GlucoGuardSleep.com.
Contact: Phone: 817-525-0057
Email: info@GlucoGuardSleep.com
Cannot view this image? Visit: https://images.newsfilecorp.com/files/7822/224435_0235dd85640e0901_002full.jpg
Image 2
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/224435_0235dd85640e0901_002full.jpg
About AMERICAN DIVERSIFIED HOLDINGS CORPORATION
www.UniversalWellnessAI.com
www.UniversalWellnessShop.com
John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
Email: JC@American-Diversified.com
Social Media:
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.
Zachary Smith commented, "ADHC provides the ideal platform for the commercialization of GlucoGuard. Both Bill and I are eager to bring this life-saving technology to market, helping millions of diabetic patients-both adults and children-better manage their glucose levels with greater safety and ease."
Bill Colone added, "Hypoglycemia, particularly during sleep, is a persistent and dangerous issue for diabetic patients, often leading to serious consequences like the dreaded 'Death in Bed' syndrome. GlucoGuard's technology offers a game-changing solution to this pressing problem."
Key Development Partnerships
The GlucoGuard system is being developed in collaboration with three key partners:
A leading U.S. research university.
A highly respected biomedical and defense engineering firm.
A top publicly traded company in the Continuous Glucose Monitoring (CGM) sector.
Further details on these collaborations will be disclosed soon.
Cutting-Edge Technology for Unmet Medical Needs
GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest.
"The GlucoGuard invention is a significant leap forward in addressing one of the most dangerous complications of diabetes," said ADHC management. "We are thrilled to welcome Zachary Smith and his innovative team to ADHC, and we're committed to fast-tracking the development and commercialization of this much-needed technology."
About Artificial Intelligence and Health Care
A recent report from the Mayo Clinic identified three potential benefits of AI in healthcare:
Improving outcomes for both patients and clinical teams.
Lowering healthcare costs.
Benefitting population health.
From preventive screenings to diagnosis and treatment, AI is being used throughout the continuum of care today. Two examples are Preventive Health Care and Risk Assessment.
Cancer Screenings that use radiology can leverage AI to help produce results faster. A noted example is analyzing kidney images in a laborious 45 minute process. AI automated process can reduce this analysis to minutes, saving time, money and giving a more accurate diagnosis.
Pre-diabetes patients with no notable symptoms can be screened using AI to determine which type of diabetes they are at risk for and begin preventative care.
See AI in healthcare: The future of patient care and health management - Mayo Clinic Press.
About the Diabetes Market
The diabetes market is poised for substantial growth, with the U.S. market valued at $28 billion, underscoring the vast potential for GlucoGuard's adoption.
For more information on the $28 billion diabetes market, visit: United States Diabetes Market Report.
The Continuous Glucose Monitoring (CGM) sector, valued at $6.8 billion, further emphasizes the critical demand for advanced glucose management solutions.
For details on the CGM market, visit: Continuous Glucose Monitoring Market.
Cannot view this image? Visit: https://images.newsfilecorp.com/files/7822/224435_0235dd85640e0901_001full.jpg
Image 1
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/224435_0235dd85640e0901_001full.jpg
About IMD Solutions, Inc.
IMD Solutions, Inc. is a Nevada-based medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, IMD Solutions is at the forefront of diabetes management technology.
For more information, visit: www.GlucoGuardSleep.com.
Contact: Phone: 817-525-0057
Email: info@GlucoGuardSleep.com
Cannot view this image? Visit: https://images.newsfilecorp.com/files/7822/224435_0235dd85640e0901_002full.jpg
Image 2
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/224435_0235dd85640e0901_002full.jpg
About AMERICAN DIVERSIFIED HOLDINGS CORPORATION
www.UniversalWellnessAI.com
www.UniversalWellnessShop.com
John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
Email: JC@American-Diversified.com
Social Media:
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.
Bullish
Recent ADHC News
- American Diversified Holdings Operating Division GlucoGuard Retains Global Contract Research Organization (CRO) to Begin Patient Studies as Required by the FDA • Newsfile • 04/01/2026 12:30:00 PM
- American Diversified Holdings Corporation (ADHC) Announces Internal Technology Initiative Within Universal Wellness AI Division • Newsfile • 01/06/2026 02:00:00 PM
- GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program • Newsfile • 11/25/2025 02:00:00 PM
- GlucoGuard Receives $43 Million Enterprise Valuation From Prominent CFA Led Harbinger Research • Newsfile • 11/04/2025 02:00:00 PM
- American Diversified Holdings Corporation Receives $5,000,000 (Five Million) Financing Commitment from an Institutional Investment Fund • Newsfile • 10/16/2025 01:00:00 PM
- GlucoGuard Receives Scope of Work (SOW) Proposal from Arete Bioscience for FDA Recommended Sleep Study • Newsfile • 10/14/2025 10:00:00 AM
